IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 97 filers reported holding IMMUNOVANT INC in Q2 2022. The put-call ratio across all filers is 0.07 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,148 | +182.1% | 29,911 | +39.5% | 0.00% | +100.0% |
| Q2 2023 | $407 | +20.1% | 21,441 | -2.0% | 0.00% | – |
| Q1 2023 | $339 | -23.8% | 21,889 | -12.6% | 0.00% | -100.0% |
| Q4 2022 | $445 | -99.7% | 25,043 | -0.1% | 0.00% | – |
| Q3 2022 | $140,000 | +44.3% | 25,056 | +0.3% | 0.00% | – |
| Q2 2022 | $97,000 | -29.7% | 24,989 | -0.2% | 0.00% | – |
| Q1 2022 | $138,000 | -35.2% | 25,031 | 0.0% | 0.00% | – |
| Q4 2021 | $213,000 | -2.3% | 25,031 | -0.3% | 0.00% | – |
| Q3 2021 | $218,000 | -17.4% | 25,095 | +0.4% | 0.00% | – |
| Q2 2021 | $264,000 | -51.3% | 25,003 | -26.0% | 0.00% | -100.0% |
| Q1 2021 | $542,000 | -65.3% | 33,800 | 0.0% | 0.00% | -50.0% |
| Q4 2020 | $1,561,000 | +40.4% | 33,800 | +7.0% | 0.00% | +100.0% |
| Q3 2020 | $1,112,000 | +161.0% | 31,600 | +80.6% | 0.00% | 0.0% |
| Q2 2020 | $426,000 | – | 17,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpine Global Management, LLC | 4,448,017 | $17,347,000 | 4.39% |
| Deep Track Capital, LP | 9,455,000 | $36,875,000 | 2.42% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 233 | $60,000,000 | 0.63% |
| Octagon Capital Advisors LP | 579,061 | $2,258,000 | 0.60% |
| Eventide Asset Management | 5,372,512 | $20,953,000 | 0.45% |
| WITTENBERG INVESTMENT MANAGEMENT, INC. | 174,000 | $679,000 | 0.29% |
| Frazier Life Sciences Management, L.P. | 585,759 | $2,284,000 | 0.22% |
| BCK CAPITAL MANAGEMENT LP | 54,293 | $212,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 777,590 | $3,033,000 | 0.12% |
| Bridgefront Capital, LLC | 15,649 | $61,000 | 0.07% |